$11.21
-0.23[-2.01%]
At close: Apr 23
$11.21
0[0.00%]
After Hours: 4:00PM EDT
KalVista Pharma
(NASDAQ:KALV)Latest News for KalVista Pharma Stock (NASDAQ:KALV)
KalVista Pharma Stock (NASDAQ: KALV)
Categories: All
Thursday, April 11, 2024
Tuesday, March 12, 2024
- HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $24 Price TargetBenzinga Newsdesk - Mar 12, 2024, 6:56AM
- KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary AngioedemaBenzinga Newsdesk - Mar 12, 2024, 6:38AM
Monday, March 11, 2024
Friday, March 08, 2024
Monday, February 26, 2024
Tuesday, February 20, 2024
Friday, February 16, 2024
Thursday, February 15, 2024
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Feb 15, 2024, 8:05AM
- KalVista Pharmaceuticals Has Priced The Public Offering Of 7.02M Shares At $15.25/Share And Pre-funded Warrants To Purchase 3.48M Shares, For Gross Proceeds Of Around $160.1MBenzinga Newsdesk - Feb 15, 2024, 6:32AM
Wednesday, February 14, 2024
- KalVista Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Pre-Funded WarrantsBenzinga Newsdesk - Feb 14, 2024, 4:40PM
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga Insights - Feb 14, 2024, 4:31PM
- Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Feb 14, 2024, 7:49AM
- HC Wainwright & Co. Maintains Buy on KalVista Pharma, Raises Price Target to $24Benzinga Newsdesk - Feb 14, 2024, 6:34AM
Tuesday, February 13, 2024
- Needham Maintains Buy on KalVista Pharma, Raises Price Target to $35Benzinga Newsdesk - Feb 13, 2024, 2:18PM
- What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday?Vandana Singh - Feb 13, 2024, 11:02AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Feb 13, 2024, 8:06AM
- KalVista Pharmaceuticals Announced Results From The Phase 3 Konfident Trial Demonstrating Statistically And Clinically Significant Efficacy Of Sebetralstat As Oral On-demand Therapy For Hereditary AngioedemaBenzinga Newsdesk - Feb 13, 2024, 6:38AM
Friday, February 09, 2024
Friday, February 02, 2024
Tuesday, January 30, 2024
Monday, January 22, 2024
Wednesday, January 17, 2024
Thursday, January 11, 2024
Monday, January 08, 2024
Tuesday, January 02, 2024
Wednesday, December 20, 2023
Thursday, December 07, 2023
Monday, November 13, 2023
Friday, September 29, 2023
- KalVista Pharma Board Member Awarded $94K Worth of Stock OptionsBenzinga Insights - Sep 29, 2023, 11:00AM
- KalVista Pharma Director Awarded $94K Worth of Stock OptionsBenzinga Insights - Sep 29, 2023, 11:00AM
- Director at KalVista Pharma Acquires Company Stock Options Worth 10,000 SharesBenzinga Insights - Sep 29, 2023, 11:00AM
Thursday, September 14, 2023
Friday, September 08, 2023
Thursday, September 07, 2023
Tuesday, August 22, 2023
Wednesday, August 02, 2023
Monday, July 10, 2023
Friday, July 07, 2023
- KalVista Pharmaceuticals shares are trading higher after the company issued better-than-expected Q4 EPS.Benzinga Newsdesk - Jul 7, 2023, 10:38AM
- Recap: KalVista Pharma Q4 EarningsBenzinga Insights - Jul 7, 2023, 7:10AM
- KalVista Appointed Brian J.G. Pereira As Chairman Of Board of Directors, Promoted Benjamin Palleiko To The Role Of President Of The CompanyBenzinga Newsdesk - Jul 7, 2023, 6:37AM
- KalVista Pharma Q4 EPS $(0.77) Beats $(0.89) Estimate; Cash, Cash Equivalents & Marketable Securities Of $149.4M Providing Runway Into 2025Benzinga Newsdesk - Jul 7, 2023, 6:33AM